UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 6, 2014
SAVIENT PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | 0-15313 | 13-3033811 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
400 Crossing Boulevard Bridgewater, NJ |
08807 | |||||
(Address of Principal Executive Offices) |
(Zip Code) |
Registrants telephone number, including area code: (732) 418-9300
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
As previously announced, on October 14, 2013, Savient Pharmaceuticals, Inc. (the Company) and its subsidiary, Savient Pharma Holdings, Inc. (collectively, the Debtors), filed voluntary petitions (the Chapter 11 Cases) for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the Bankruptcy Court).
As previously disclosed, on December 13, 2013, the Bankruptcy Court approved a final provisional order on the Debtors use of cash collateral. The final form of order did not attach a final cash collateral budget and contemplated that the Debtors, the Official Committee of Unsecured Creditors and the Senior Secured Noteholders would roll forward the existing budget previously filed with the Bankruptcy Court (included in the Debtors Initial Monthly Operating Report attached to the Companys Current Report on Form 8-K filed on November 6, 2013) and work in good faith with regard to certain line items in the budget. On December 30, 2013, the Debtors filed a Notice of Current Working Draft of Cash Collateral Budget and Illustrative Sources and Uses with the Bankruptcy Court attaching the current working draft of the cash collateral budget and an illustrative sources and uses calculation. On January 6, 2014, the Debtors, the Official Committee of Unsecured Creditors and the Unofficial Committee of Senior Secured Noteholders agreed on the final form of cash collateral budget, which assumes the closing of the sale of substantially all of the Debtors assets and certain liabilities to Crealta Pharmaceuticals LLC (the Sale Transaction) during the week ending January 10, 2014. The final form of cash collateral budget was filed with the Bankruptcy Court on January 6, 2014 with the Certification of Counsel Regarding Final Cash Collateral Order and Budget (the Certification).
Closing of the Sale Transaction remains subject to various closing conditions.
The Certification is attached hereto as Exhibit 99.1.
Cautionary Statement Regarding the Certification
The Company cautions investors and potential investors not to place undue reliance upon the information contained in the Certification, which was not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The information contained in the Certification is limited in scope and has been prepared solely for the purpose of complying with requirements of the Bankruptcy Court. The financial information contained in the Certification was not reviewed by independent accountants, is in a format prescribed by applicable bankruptcy laws, and is subject to future adjustment. The financial information contained in the Certification is not prepared in accordance with accounting principles generally accepted in the United States (GAAP) and, therefore, may exclude items required by GAAP, such as certain reclassifications, eliminations, accruals, valuations and disclosures. The financial information contained in the Certification also relates to periods which are different from the historical periods required in the Companys reports pursuant to the Securities Exchange Act of 1934, as amended (the Exchange Act).
Cautionary Statement Regarding Forward-Looking Statements
This Current Report on Form 8-K and Exhibit 99.1 hereto (collectively, this Current Report) may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations, estimates, forecasts, and projections as well as the current beliefs and assumptions of the Companys management. Forward-looking statements may be identified by words such as anticipate, estimate, expect, project, intend, plan, believe, may, predict, will, would, could, should, target and similar expressions. All statements contained in this Current Report that are not statements of historical fact and other estimates, projections, future trends and the outcome of events that have not yet occurred referenced in this Current Report should be considered forward-looking statements. Actual results or events could differ materially from those indicated in forward-looking statements as a result of risks and uncertainties, including, among others, the potential adverse impact of the Chapter 11 Cases on the Companys liquidity or results of operations, changes in the Companys ability to meet financial obligations during the Chapter 11 process or to maintain contracts that are critical to the Companys operations, the outcome or timing of the Chapter 11 process and the related proposed asset sale, the effect of the Chapter 11 Cases or proposed asset sale on the Companys relationships with third parties, regulatory authorities and employees, proceedings that may be brought by third parties in connection with the Chapter 11 process or the proposed asset sale or conditions to the proposed asset sale, and the timing or amount of any distributions to the Companys stakeholders. Many of such factors relate to events and circumstances that are beyond the Companys control. You should not place undue reliance on forward-looking statements. The Company does not assume any obligation to update the information contained in this Current Report.
Limitation on Incorporation by Reference
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report is being furnished for informational purposes only and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing. The filing of this current report (including Exhibit 99.1 attached hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD.
Additional Information regarding the Chapter 11 Cases
Additional information regarding the Chapter 11 Cases is available at www.gcginc.com/cases/svnt. This link is provided for convenience only. Such information shall not be deemed to be incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
99.1 | Certification of Counsel Regarding Final Cash Collateral Order and Budget, dated January 6, 2014. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SAVIENT PHARMACEUTICALS, INC. | ||||||||
Date: January 7, 2014 | By: | /s/ Philip K. Yachmetz | ||||||
Name: | Philip K. Yachmetz | |||||||
Title: | Co-President and Chief Business Officer |
INDEX TO EXHIBITS
Exhibit No. |
Description | |
99.1 | Certification of Counsel Regarding Final Cash Collateral Order and Budget, dated January 6, 2014. |
Exhibit 99.1
IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - | x | |||
: | Chapter 11 | |||
In re: | : | |||
: | Case No. 13-12680 (MFW) | |||
SAVIENT PHARMACEUTICALS, INC., | : | |||
et al., | : | Jointly Administered | ||
: | ||||
Debtors.1 | : | Related to Docket Nos. 16, 43, 250, 295 | ||
: | ||||
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - | x |
CERTIFICATION OF COUNSEL REGARDING
FINAL CASH COLLATERAL ORDER AND BUDGET
The undersigned, counsel to the debtors and debtors-in-possession in the above-
captioned cases (the Debtors), hereby certifies as follows:
On October 14, 2013, the Debtors filed the Debtors Motion For Interim And
Final Orders Under 11 U.S.C. §§ 105, 361, 362, 363, 507(b), Fed. R. Bankr. P. 4001, 6004(h),
7062 And 9014 And Del. Bankr. L.R. 4001-2 (I) Authorizing The Debtors To Use Cash
Collateral, (II) Granting Adequate Protection To Prepetition Secured Noteholders, And
(III) Scheduling Final Hearing Pursuant To Fed. R. Bankr. P. 4001(B) [Docket No. 16] (the
Motion).
On October 16, 2013, United States Bankruptcy Court for the District of
Delaware (the Bankruptcy Court) entered the Interim Order Under 11 U.S.C. §§ 105, 361, 362,
363, 507(b), Fed. R. Bankr. P. 4001, 6004(h), 7062, And 9014 And Del. Bankr. L.R. 4001-2
(I) Authorizing The Debtors To Use Cash Collateral, (II) Granting Adequate Protection to
1 | The Debtors and the last four digits of their respective taxpayer identification numbers are as follows: |
Savient Pharmaceuticals, Inc. (3811); and Savient Pharma Holdings, Inc. (0701). The address of the |
Debtors corporate headquarters is 400 Crossing Boulevard, 3rd Floor, Bridgewater, New Jersey 08807. |
Docket No. 306 Date Filed: 1/6/14 |
Prepetition Secured Noteholders, (III) Scheduling a Final Hearing Pursuant to Fed. R. Bankr. P.
4001(B), and (IV) Granting Related Relief [Docket No. 43] (the Interim Order).
On December 13, 2013, the Bankruptcy Court entered the Final Provisional Order
Under 11 U.S.C. §§ 105, 361, 362, 363, 507(b), Fed. R. Bankr. P. 4001, 6004(h), 7062, And
9014 And Del. Bankr. L.R. 4001-2 (I) Authorizing The Debtors To Use Cash Collateral,
(II) Granting Adequate Protection To Prepetition Secured Noteholders, And (III) Granting
Related Relief [Docket No. 250] (the Final Provisional Order).2
The Final Provisional Order provided that any party in interest objecting to the
entry of such order was required to file and serve a written objection by December 27, 2013. No
objection to entry of the Final Provisional Order was filed or served.
The Final Provisional Order did not attach a final cash collateral Budget. Rather,
the order provided that [d]uring the period from December 13, 2013 to December 20, 2013, the
Parties shall roll forward the existing Budget which shall be deemed adjusted to increase the 13-
week cash and accrual line items consistent with previous weeks to account for the later than
anticipated closing of the Sale and the fees and costs resulting therefrom and shall work in good
faith with regard to certain line items in the Budget. Final Provisional Order at ¶ 18(d), fn. 4.
On December 30, 2013, the Debtors filed the Notice Of Filing Of Current
Working Draft Of Cash Collateral Budget And Illustrative Sources And Uses [Docket No. 295],
which notice attached, among other things, a working draft of the cash collateral Budget.
The Debtors, the Unofficial Committee of Senior Secured Noteholders and the
Committee have negotiated in good faith and agreed on the final form of cash collateral Budget.
2 | Capitalized terms used herein but not defined herein shall have the meanings ascribed to such terms in the |
Final Provisional Order. |
2
Attached hereto are the final forms of the 13-Week Budget (Exhibit A) and Accrual Budget (Exhibit A-1).
Dated: | Wilmington, Delaware | |||||
January 6, 2014 | ||||||
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP | ||||||
/s/ Dain A. De Souza | ||||||
Anthony W. Clark (I.D. No. 2051) | ||||||
Dain A. De Souza (I.D. No. 5737) | ||||||
One Rodney Square | ||||||
P.O. Box 636 | ||||||
Wilmington, Delaware 19899-0636 | ||||||
Telephone: (302) 651-3000 | ||||||
Fax: (302) 651-3001 | ||||||
- and -
| ||||||
Kenneth S. Ziman | ||||||
David M. Turetsky | ||||||
Four Times Square | ||||||
New York, New York 10036-6522 | ||||||
Telephone: (212) 735-3000 | ||||||
Fax: (212) 735-2000 | ||||||
- and -
| ||||||
COLE, SCHOTZ, MEISEL, FORMAN | ||||||
& LEONARD, P.A. | ||||||
David R. Hurst (I.D. No. 3743) | ||||||
J. Kate Stickles (I.D. No. 2917) | ||||||
500 Delaware Avenue, Suite 1410 | ||||||
Wilmington, Delaware 19801 | ||||||
Telephone: (302) 652-3131 | ||||||
Facsimile: (302) 652-3117 | ||||||
Counsel for Debtors and Debtors-in-Possession |
3
EXHIBIT A
13-Week Budget
EXHIBIT A: 13-WEEK BUDGET
Week | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | TOTAL | ||||||||||||||||||||||||||||||||||||||||||||||||||
Actual Weeks 1-10 |
Est. W/E |
Est. W/E |
Est. W/E |
Est. W/E |
Est. W/E |
Est. W/E |
Est. W/E |
Est. W/E |
Est. W/E |
Est. W/E |
Est. W/E |
Est. W/E |
Est. W/E |
|||||||||||||||||||||||||||||||||||||||||||||||||||
Beginning Cash Balance |
$27,744 | $19,777 | $19,556 | $18,580 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total Cash Collections |
$4,561 | $400 | $400 | $475 | $5,836 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disbursements: |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Payroll Related |
(2,373 | ) | - | (493 | ) | (1,174 | ) | - | - | - | - | - | - | - | - | - | - | (4,040 | ) | |||||||||||||||||||||||||||||||||||||||||||||
Concur |
(202 | ) | (50 | ) | (50 | ) | (50 | ) | - | - | - | - | - | - | - | - | - | - | (352 | ) | ||||||||||||||||||||||||||||||||||||||||||||
Board Fees |
(105 | ) | - | (97 | ) | (42 | ) | - | - | - | - | - | - | - | - | - | - | (244 | ) | |||||||||||||||||||||||||||||||||||||||||||||
Royalty Payments |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
Distribution |
(24 | ) | - | - | (234 | ) | - | - | - | - | - | - | - | - | - | - | (258 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
Taxes |
(32 | ) | - | - | - | - | - | - | - | - | - | - | - | - | - | (32 | ) | |||||||||||||||||||||||||||||||||||||||||||||||
Rent |
(374 | ) | - | - | - | - | - | - | - | - | - | - | - | - | - | (374 | ) | |||||||||||||||||||||||||||||||||||||||||||||||
Other (a) |
(919 | ) | (100 | ) | (569 | ) | (530 | ) | - | - | - | - | - | - | - | - | - | - | (2,118 | ) | ||||||||||||||||||||||||||||||||||||||||||||
HSR Related (a) |
(146 | ) | (100 | ) | (150 | ) | (904 | ) | - | - | - | - | - | - | - | - | - | - | (1,300 | ) | ||||||||||||||||||||||||||||||||||||||||||||
Transition |
- | (362 | ) | (3 | ) | (234 | ) | - | - | - | - | - | - | - | - | - | - | (600 | ) | |||||||||||||||||||||||||||||||||||||||||||||
Accrual Budget Amounts (f.k.a. Restructuring Costs) |
(353 | ) | (9 | ) | (14 | ) | (14 | ) | - | - | - | - | - | - | - | - | - | - | (389 | ) | ||||||||||||||||||||||||||||||||||||||||||||
Total Disbursements |
($4,528 | ) | ($621 | ) | ($1,377 | ) | ($3,182 | ) | - | - | - | - | - | - | - | - | - | - | ($9,707 | ) | ||||||||||||||||||||||||||||||||||||||||||||
Adequate Protection Payment |
($8,000 | ) | - | - | - | - | - | - | - | - | - | - | - | - | - | ($8,000 | ) | |||||||||||||||||||||||||||||||||||||||||||||||
Net Change in Cash
|
|
($7,967
|
)
|
|
($221
|
)
|
|
($977
|
)
|
|
($2,707
|
)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Ending Cash Balance |
$19,777 | $19,556 | $18,580 | $15,873 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note: | Does not reflect any cash collections or amounts under the Accrual Budget following closing (estimated on 1/10/14). |
Note: | The Budget is based on a closing of 1/10/14 for the Sale; the Budget will be adjusted upward or downward consistent with previous cash and accrual costs to account for a closing date that occurs before or after 1/10/14. |
(a) Amounts shown in weeks ending 12/27/13, 1/3/14 and 1/10/14 are estimates for all remaining disbursements to be made before and after assumed closing date (estimated on 1/10/14).
EXHIBIT A-1
Accrual Budget
EXHIBIT A-1: ACCRUAL BUDGET
ACCRUAL BUDGET | ||||||||||||||||||||||||||||||||||||
Oct-13 | Nov-13 | Dec-13 | Jan-14 | Feb-14 | Mar-14 | Apr-14 | May-14 | Total | ||||||||||||||||||||||||||||
Company Advisors: |
||||||||||||||||||||||||||||||||||||
Skadden |
$ | 1.90 | $ | 1.00 | $ | 0.75 | - | - | - | - | - | $ | 3.65 | |||||||||||||||||||||||
Lazard |
0.15 | 0.15 | 2.19 | - | - | - | - | - | 2.49 | |||||||||||||||||||||||||||
Cole Schotz |
0.18 | 0.25 | 0.45 | 0.25 | 0.28 | 0.21 | 0.26 | 0.13 | 2.00 | |||||||||||||||||||||||||||
Deloitte |
0.04 | 0.08 | 0.04 | - | - | - | - | - | 0.16 | |||||||||||||||||||||||||||
Kramer Levin |
0.10 | 0.13 | 0.09 | - | - | - | - | - | 0.31 | |||||||||||||||||||||||||||
Joelle Frank |
0.03 | 0.05 | 0.03 | - | - | - | - | - | 0.10 | |||||||||||||||||||||||||||
GCG (Claims Agent) |
0.39 | 0.08 | 0.10 | 0.08 | 0.14 | 0.08 | 0.10 | 0.03 | 0.98 | |||||||||||||||||||||||||||
Subtotal Company Advisors |
$ | 2.78 | $ | 1.73 | $ | 3.64 | $ | 0.33 | $ | 0.41 | $ | 0.29 | $ | 0.36 | $ | 0.16 | $ | 9.68 | ||||||||||||||||||
Secured Lender Advisor: |
||||||||||||||||||||||||||||||||||||
Secured Lender Counsel |
$ | 0.40 | $ | 0.30 | $ | 0.17 | $ | 0.04 | $ | 0.04 | $ | 0.04 | $ | 0.04 | $ | 0.03 | $ | 1.08 | ||||||||||||||||||
Subtotal Secured Lender Advisor |
$ | 0.40 | $ | 0.30 | $ | 0.17 | $ | 0.04 | $ | 0.04 | $ | 0.04 | $ | 0.04 | $ | 0.03 | $ | 1.08 | ||||||||||||||||||
UCC Advisors: |
||||||||||||||||||||||||||||||||||||
Legal Advisor |
- | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||
Financial Advisor |
- | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||
Other |
- | - | - | 0.03 | 0.03 | 0.03 | 0.03 | - | 0.10 | |||||||||||||||||||||||||||
Subtotal UCC Advisors |
$ | 0.00 | $ | 0.00 | $ | 0.00 | $ | 0.03 | $ | 0.03 | $ | 0.03 | $ | 0.03 | $ | 0.00 | $ | 0.10 | ||||||||||||||||||
Other Expenses: |
||||||||||||||||||||||||||||||||||||
Court and U.S. Trustee Fees |
$ | 0.03 | $ | 0.03 | $ | 0.04 | $ | 0.01 | $ | 0.01 | $ | 0.01 | $ | 0.01 | $ | 0.01 | $ | 0.12 | ||||||||||||||||||
Operational Wind-Down Expenses |
- | - | 0.03 | 0.06 | 0.06 | 0.04 | 0.04 | 0.04 | 0.27 | |||||||||||||||||||||||||||
Liquidating Trust |
- | - | - | - | - | 0.20 | - | - | 0.20 | |||||||||||||||||||||||||||
Employee-Related Costs (after-sale) |
0.08 | - | - | 1.14 | - | - | - | - | 1.22 | |||||||||||||||||||||||||||
Contingency and Expenses |
0.31 | 0.34 | 0.55 | 0.07 | 0.09 | 0.09 | 0.08 | 0.04 | 1.57 | |||||||||||||||||||||||||||
Subtotal Other |
$ | 0.42 | $ | 0.36 | $ | 0.61 | $ | 1.28 | $ | 0.15 | $ | 0.34 | $ | 0.12 | $ | 0.09 | $ | 3.38 | ||||||||||||||||||
Total |
$ | 3.59 | $ | 2.39 | $ | 4.42 | $ | 1.68 | $ | 0.63 | $ | 0.70 | $ | 0.55 | $ | 0.28 | $ | 14.24 |
Note: |
For purposes of measuring fees and expenses against the amounts set forth in this Accrual Budget, the amounts set forth in this Accrual Budget are estimated accruals, not cash payments, with the excess of accrual over actual for any month (or months) to be carried over into and increase the subsequent months Budget. |